News
In the news
23/10/2023
In the clinic for Oct. 23, 2023
Original source here.
| Company | Product | Description | Indication | Status |
| Exact Sciences Corp., of Madison, Wis. | Cologuard | Stool DNA test | Colorectal cancer (CRC) | Data from the pivotal BLUE-C trial showed the next-generation Cologuard test met all study endpoints, demonstrating 94% sensitivity for CRC at 91% specificity; the test was significantly more likely to detect cancer or precancer than fecal immunochemical testing (FIT) (94% vs. 67% and 43% vs. 23%, respectively) |
| Guardant Health Inc., of Palo Alto, Calif. | Guardant Reveal | Circulating tumor DNA blood test | Colon cancer | Initial results from the PEGASUS trial suggest Guardant Reveal may be used in post-surgical clinical management to reduce unnecessary toxicity from chemotherapy and improve the response to standard chemotherapy regimens in patients with stage III or high-risk stage II colon cancer; 34% of patients with a positive liquid biopsy result after surgery had the cancer return, while only 10% of patients with a negative result experienced a relapse |
| Oncohost Ltd., of Binyamina, Israel | Prophet test | Proteomics-based decision-support tool | Non-small-cell lung cancer | Study examining the experimental and computational analytical validity of the test was published in the Journal of Pharmaceutical & Biomedical Analysis; a strong experimental precision and accuracy performance was observed; computational precision analysis displayed high consistency for repeated samples; cross-platform analysis supported the reliability of the examined proteomic assay |
|
Notes For more information about individual companies and/or products, see Cortellis. |